1228 — Canbridge Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- HK$140.20m
- HK$144.96m
- CNY102.87m
Annual cashflow statement for Canbridge Pharmaceuticals, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -218 | -846 | -1,077 | -483 | -379 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 97.8 | 629 | 449 | 29.3 | 23.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -9.86 | 47.4 | 25 | 151 | 48.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -126 | -152 | -587 | -281 | -278 |
| Capital Expenditures | -42.5 | -153 | -5.33 | -34.8 | -40.9 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.056 | 0 | 131 | 0 | 14 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -42.4 | -153 | 126 | -34.8 | -26.9 |
| Financing Cash Flow Items | -1.73 | -6.24 | -33.1 | -16.1 | -2.13 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 97 | 679 | 854 | -20.7 | -28 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -71.4 | 347 | 385 | -295 | -326 |